Result of AGM

LungLife AI, Inc.

("LungLife" or the "Company")

Result of Annual General Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.

Full details of the voting will be available shortly on the Company website here: https://lunglifeai.com/investors/financial-information-documents-presentations/

For further information please contact:

LungLife AI, Inc.www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO 
  
Investec Bank plc (Nominated Adviser & Broker)Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
  
Goodbody (Joint Broker)Tel: +44 (0) 20 3841 6202
Tom Nicholson / Cameron Duncan 
  
Walbrook PR LimitedTel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Alice Woodings / Phillip MarriageMob: 07407 804 654 / 07867 984 082

Click HERE for the full announcement.

Block Listing Six Monthly Return

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Six Monthly Return

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

Name of applicant:LungLife AI, Inc.
Name of scheme:2010 Stock Incentive Plan2020 Stock Incentive Plan2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted:1,356,139 common shares of US $0.0001 each
Date of admission:15 November 2021
Period of return:From:15 November 2023To:15 May 2024
Balance of unallotted securities under scheme(s) from previous return:475,583201,374673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):NILNILNIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):NILNILNIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:475,583201,374673,990
Total number of securities in issue at the end of the period30,658,603
Name of contact:David Anderson, Chief Financial Officer
Telephone number of contact:+44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

For further information please contact:

LungLife AI, Inc.www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO 
  
Investec Bank plc (Nominated Adviser & Broker)Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
  
Goodbody (Joint Broker)Tel: +44 (0) 20 3841 6202
Tom Nicholson / Cameron Duncan 
  
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Alice Woodings / Phillip MarriageMob: 07407 804 654 / 07867 984 082

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

Holdings in Company

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI, Inc.
(the “Company” or “LungLife”)

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company’s website and will be posted to those shareholders who have opted out of electronic communications today.

The documents are available here: lunglifeai.com/investors/financial-information-documents-presentations/

The Company's AGM will be held at 4:00 P.M. (BST) on 5 June 2024, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. The Company will announce details of how to listen to the meeting remotely and any other significant changes to the meeting arrangements via RNS and on LungLife’s website at investors.lunglifeai.com/

Shareholders are strongly encouraged to vote by proxy, whether or not you plan to attend the Company’s Annual General Meeting in person. You may register your votes on the resolutions of the Annual General Meeting by completing and returning the proxy form that accompanies this Notice in accordance with the instructions printed on the proxy form.

If shareholders’ holding of Common Shares is by way of dematerialised depository interests representing underlying Common Shares (“Depository Interests”), they can vote through the CREST system or by returning a Form of Instruction to the Depositary. Further instructions are set out in the Notes to the Notice of Annual General Meeting.

The resolutions to be proposed at the Annual General Meeting are summarised in the Notice of AGM.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company’s website as soon as practicably possible after the AGM.

LungLife to present at US National Cancer Institute’s Early Detection Research Network Meeting

LungLife AI, Inc.
(the “Company” or “LungLife”)

LungLife to present at US National Cancer Institute’s Early Detection Research Network Meeting

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces it has been invited to present at the National Cancer Institute’s (“NCI”) Early Detection Research Network (“EDRN”) meeting in Tempe, Arizona on 17 April 2024.

The EDRN is a division of the United States NCI, the federal government’s principal agency for cancer research and training, which works collaboratively amongst its members to bring new diagnostic biomarkers to clinical use.

In October 2022, LungLife was selected to participate in the Lung Cancer Biomarker Development Laboratory of the EDRN, combining LungLB® with imaging to assist early detection research, as well as validate combined test performance in patients with indeterminate lung nodules.

In this meeting, LungLife will present the LungLB® test, including results from the validation study and information on the Early Access Program, and describe its role in the ongoing EDRN study for indeterminate lung nodules to a group of over 300 investigators from the NCI, academic institutions and industry focused on early cancer detection.

Paul Pagano, CEO of LungLife AI, said “We are excited that through our ongoing EDRN partnership we have the opportunity to present at this meeting to collaborators and potential end users of LungLB®.

“The work of the EDRN closely aligns with LungLife’s mission to drive the early detection of lung cancer and will provide further clinical evidence for the LungLB® technology as well as widen awareness of our technology with leading US investigators and diagnostics industry partners.”

Download the full announcement HERE.

Preliminary audited results for year ended 31 December 2023

LungLife AI, Inc.
(the “Company” or “LungLife”)

Preliminary audited results for year ended 31 December 2023

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2023.

Summary and Highlights for the year and post-period end:

Commenting, Paul Pagano, Chief Executive Officer of LungLife, said:“2023 was a year of considerable achievement culminating in the conclusion of our multi-site clinical validation study, which was the primary objective at our IPO. A positive predictive value of over 80% in smaller indeterminate nodules is significant. This is where physicians consistently indicate the greatest unmet need and where currently available tools fall short.

“In March 2024 we concluded our fund raising to commence the commercialisation of our test. This enables us to initiate our Early Access Program, submit forms to MolDX for technical assessment for Medicare coverage consideration, and continue other matters necessary for commercialisation. We have also started the process of considering all strategic options to get the LungLB test into the hands of patients who need it most.

“Our revised cash runway to April 2025 has required significant cost reductions, the largest being to headcount and salaries for the executive team. We are now a smaller team focussed on the key commercialisation activities. Those who have left the Company played an important role in delivering our achievements to date and on behalf of the whole Board, I would like to thank them for their efforts.”

To see the full results statement, click HERE.

Notice of Results

LungLife AI Inc

(the “Company” or “LungLife”)

Notice of Results

Investor Presentation

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2023 on Thursday 4 April 2024.

Investor presentation

Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial Officer, will be hosting a live online presentation relating to the full year results via the Investor Meet Company platform at 4.00pm (BST) on Friday 5 April 2024.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and register for the presentation here. Investors who already follow LungLife on the Investor Meet Company platform will automatically be invited.

A recording of the presentation and a PDF of the slides used will also be available on the LungLife website: https://lunglifeai.com/investors/

Holding(s) in Company

Holding(s) in Company

Admission of New Shares and PDMR Dealing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

LungLife AI, Inc.
(the “Company” or “LungLife”)

Admission of New Shares and PDMR Dealing

LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that, further to the Company announcements on 4 March 2025, 5 March 2024 and 21 March 2024, 5,172,621 new shares of common stock have been admitted to trading on AIM under the ticker symbol LLA and ISIN USU5500L1128 in connection with the Fundraising.

The Company also announces that it has been notified of transactions in the Company’s Common Shares by directors in connection with the Fundraising, as detailed in the Appendix to the announcement.

The Company’s total issued share capital now consists of 30,658,603 Common Shares of US$0.0001 each with one voting right per Common Share. There are no Common Shares held in treasury. The total number of voting rights in the Company is therefore 30,658,603. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company.

Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings as defined in the Company’s announcement of 4 March 2024.

For further information please contact:

LungLife AI, Inc.www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO 
  
Investec Bank plc (Nominated Adviser & Joint Broker)Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
  
Goodbody Stockbrokers UC (Joint Broker) Tom Nicholson / Cameron Duncan / William Hall  Tel: +44 (0)20 3841 6202
Walbrook PR Limited Tel: +44 (0)20 7933 8780
Paul McManus / Alice Woodings / Phillip Marriageor LungLifeAI@walbrookpr.com

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

APPENDIX

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)NamePaul Pagano
2Reason for the notification
a)Position/statusChief Executive Officer
b)Initial notification/amendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc.
b)LEI549300VBVDIF0Y3OVI38
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Identification codeCommon shares of US$0.0001 each ISIN: USU5500L1128
b)Nature of the transactionParticipation in Fundraising
c)Price(s) and volume(s)Price(s) Volume(s) 35p 14,285
d)Aggregated information -   Aggregated volume  -   Price  N/A N/A
e)Date of the transaction22 March 2024
f)Place of the transactionOutside a Trading Venue
1Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)NameDavid Anderson
2Reason for the notification
a)Position/statusChief Financial Officer
b)Initial notification/amendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc.
b)LEI549300VBVDIF0Y3OVI38
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Identification codeCommon shares of US$0.0001 each ISIN: USU5500L1128
b)Nature of the transactionParticipation in Fundraising
c)Price(s) and volume(s)Price(s) Volume(s) 35p 14,285
d)Aggregated information -   Aggregated volume  -   Price  N/A N/A
e)Date of the transaction22 March 2024
f)Place of the transactionOutside a Trading Venue
1Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)NameGordon Roy Davis
2Reason for the notification
a)Position/statusNon-Executive Chairman
b)Initial notification/amendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc.
b)LEI549300VBVDIF0Y3OVI38
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Identification codeCommon shares of US$0.0001 each ISIN: USU5500L1128
b)Nature of the transactionParticipation in Fundraising
c)Price(s) and volume(s)Price(s) Volume(s) 35p 28,571
d)Aggregated information -   Aggregated volume  -   Price  N/A N/A
e)Date of the transaction22 March 2024
f)Place of the transactionOutside a Trading Venue
1Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)NameAndrew Boteler
2Reason for the notification
a)Position/statusNon-Executive Director
b)Initial notification/amendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameLungLife AI, Inc.
b)LEI549300VBVDIF0Y3OVI38
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Identification codeCommon shares of US$0.0001 each ISIN: USU5500L1128
b)Nature of the transactionParticipation in Fundraising
c)Price(s) and volume(s)Price(s) Volume(s) 35p 14,285
d)Aggregated information -   Aggregated volume  -   Price  N/A N/A
e)Date of the transaction22 March 2024
f)Place of the transactionOutside a Trading Venue

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE “UNITED STATES”), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into the United States, or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act (“Regulation S”)), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States